Tanezumab

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Bone Metastasis

Conditions

Bone Metastasis, Cancer Pain

Trial Timeline

Oct 28, 2015 → Jun 25, 2021

NCT ID

NCT02609828

About Tanezumab

Tanezumab is a phase 3 stage product being developed by Eli Lilly for Bone Metastasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02609828. Target conditions include Bone Metastasis, Cancer Pain.

What happened to similar drugs?

10 of 20 similar drugs in Bone Metastasis were approved

Approved (10) Terminated (1) Active (9)

🔄Denosumab + Zoledronic AcidDaiichi SankyoPhase 3

🔄Arzoxifene + PlaceboEli LillyPhase 3

🔄Anastrozole + TamoxifenAstraZenecaPhase 3

🔄zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplementsNovartisPhase 3

🔄Zoledronic acidNovartisPhase 3

🔄Zoledronic acid + LetrozoleNovartisPhase 3

🔄Zoledronic acidNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02609828	Phase 3	Completed	Oct 28, 2015	Jun 25, 2021	Bone Metastasis

Competing Products

20 competing products in Bone Metastasis

See all competitors

Product	Company	Stage	Hype Score
Denosumab + Zoledronic Acid	Daiichi Sankyo	Phase 3	40
Enzalutamide	Astellas Pharma	Phase 2	35
Enzalutamide	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Tacrolimus	Astellas Pharma	Phase 2	35
Merestinib	Eli Lilly	Phase 1	21
FORTEO + Placebo	Eli Lilly	Phase 1	29
Arzoxifene + Placebo	Eli Lilly	Phase 3	40
Anastrozole + Tamoxifen	AstraZeneca	Phase 3	40
zoledronic acid + placebo to zoledronic acid + Risedronate + Placebo to risedronate + Calcium and vitamin D supplements	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Zoledronic acid + Letrozole	Novartis	Phase 3	40
Zoledronic acid	Novartis	Phase 3	40
Nilotinib	Novartis	Phase 1	29
Reclast (ZOL446, zoledronic acid)	Novartis	Approved	43
Zoledronic acid	Novartis	Phase 3	32
Zoledronic Acid + Risedronate + Placebo to Risedronate + Placebo to Zoledronic Acid	Novartis	Phase 3	40
zoledronic acid	Novartis	Phase 1	29
Ruxolitinib continuous therapy	Novartis	Phase 2	39
zoledronic acid	Novartis	Approved	43